Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Activating Transcription Factor 3 (ATF3)
100%
Cisplatin
100%
Non-small Cell Lung Carcinoma Cells
100%
Platin
62%
Cytotoxicity
37%
Novel Therapeutics
25%
Non-small Cell Lung Cancer (NSCLC)
25%
Cisplatin-induced
25%
Cisplatin Cytotoxicity
25%
Gene Expression
12%
Inducer
12%
Tumor
12%
Vorinostat
12%
Histone Deacetylase Inhibitor (HDACi)
12%
Putative Drug Targets
12%
Cancer Mortality
12%
Combination Chemotherapy
12%
Most Common Cause
12%
Overall Survival
12%
Cancer Causes
12%
RNA-seq Analysis
12%
Lung Tissue
12%
FDA-approved Drugs
12%
Drug Compounds
12%
Novel Regulator
12%
Combination Regimen
12%
JNK Activation
12%
Cisplatin Resistance
12%
Synergistic Cytotoxicity
12%
Compound Screen
12%
Carcinoma Cell Line
12%
Pharmacology, Toxicology and Pharmaceutical Science
Cisplatin
100%
Non Small Cell Lung Cancer
100%
Activating Transcription Factor 3
100%
Cytotoxicity
75%
Vorinostat
12%
Histone Deacetylase Inhibitor
12%
Overall Survival
12%
Cancer Mortality
12%
Transcriptome
12%
Chemotherapy Regimens
12%
Neuroscience
Cisplatin
100%
Activating Transcription Factor 3
100%
Cytotoxicity
75%
Cell Line
37%
Gene Expression
12%
Enhancer Region
12%
Transcriptome
12%
RNA-Seq
12%
Histone Deacetylase Inhibitor
12%
Vorinostat
12%
Chemotherapy
12%
Biochemistry, Genetics and Molecular Biology
Cisplatin
100%
Activating Transcription Factor 3
100%
Cytotoxicity
75%
Gene Expression
12%
RNA Sequencing
12%
Gene Expression Profiling
12%
Cancer Mortality
12%
Enhancer Region
12%
Histone Deacetylase
12%
Overall Survival
12%
Combination Chemotherapy
12%